Skip to content
DataLookout
Menu

LF-FOLFOXNCT07941843

Lactoferrin Supplementation for FOLFOX-Related Toxicities in Colorectal Cancer

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Incidence of Oxaliplatin-Induced Peripheral Neuropathy
Timeframe: From baseline before initiation of FOLFOX therapy to 3 months after initiation of FOLFOX therapy.

Arms and interventions

Standard FOLFOX ChemotherapyActive comparator

Participants assigned to the control group will receive standard FOLFOX chemotherapy consisting of oxaliplatin, 5-fluorouracil, and leucovorin according to the routine oncology treatment protocol.

FOLFOX Plus LactoferrinExperimental

Participants assigned to the intervention group will receive standard FOLFOX chemotherapy plus oral lactoferrin supplementation (Pravotin) at a dose of 100 mg twice daily, initiated at the first chemotherapy cycle and continued throughout the planned chemotherapy course.

Dietary supplements: Lactoferrin

Drugs: FOLFOX chemotherapy regimen